As we enter the third year of the COVID-19 pandemic, we recognize that although the pandemic isn’t over, it has transitioned into a new phase. In light of a rapidly changing external environment, we have made the difficult decision to wind down operations for PRL effective 12/31/22 and make a strategic pivot to center our lab services on non-clinical lab customers. This shift points our company to areas where we can make the most significant impact in the most differentiated way. We will no longer be accepting samples after 12/27 and will reassign our sequencing core and biosurveillance activities to our sister company Neochromosome’s biofoundry operations. We are grateful to everyone who contributed to making PRL an invaluable public health resource and a successful business during the COVID-19 pandemic. Thank you for the opportunity to serve. The PRL Team